News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AKAN
RDHL
MDGL - Shares Outstanding 17.1M
https://finance.yahoo.com/quote/MDGL/key-statistics?p=MDGL
Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis
https://finance.yahoo.com/news/madrigal-announces-positive-topline-results-120000055.html
GLDG https://www.goldmining.com
Outstanding Shares - 158,733,864 - 11/09/2022
https://www.otcmarkets.com/stock/GLDG/security
TENX
COMS CHARTS
$7.94 "Consensus Analyst Price Target $150.00"
https://www.marketbeat.com/stocks/NASDAQ/INM/price-target
INM-755 for the treatment of Epidermolysis Bullosa (“EB”)
Enrollment and patient treatment in the Company’s Phase 2 clinical trial, 755-201-EB, continued throughout the fourth quarter and, to date, nine patients been enrolled and completed treatment in the study. The 755-201-EB study is designed to enroll up to 20 patients. InMed is evaluating the safety of INM-755 (cannabinol) cream and its preliminary efficacy in treating symptoms and wound healing over a 28-day treatment period. This study marks the first time cannabinol (“CBN”) has advanced to a Phase 2 clinical trial to be investigated as a therapeutic option to treat a disease.
In the fiscal fourth quarter, based on the safety data of the first five adult patients who completed treatment with INM-755 CBN cream for the treatment of EB in the Phase 2 clinical trial, an independent Data Monitoring Committee (“DMC”) agreed it is safe to allow the enrollment of adolescent patients, defined as persons aged twelve to seventeen. The first adolescent patient with EB has been enrolled into the clinical trial and has completed treatment at the clinical site in Greece during the summer.
Following a period of downtime during the summer months, patient screening and enrollment has now recommenced at sites across Europe. The Company anticipates that the inclusion of adolescents will have a positive impact on the enrollment rate for the remainder of the clinical trial. Enrollment is anticipated to complete during the calendar year 2022.
InMed’s Phase 2 clinical trial now has nine clinical trial sites fully activated to screen and enroll patients. Two more sites are expected to be fully activated soon. The clinical trial is taking place in seven countries including Austria, Germany, Greece, France, Italy, Israel and Spain.
INM-088 for the treatment of glaucoma
In the fourth fiscal quarter, the Company completed a pre-Investigational New Drug (“pIND”) application discussion with the U.S. Food and Drug Administration (“FDA”) regarding manufacturing, preclinical studies and early clinical development plans for INM-088, a CBN formulation in development for glaucoma. The Company gained alignment with FDA on the design of the initial Phase 1-2 clinical trial to gather preliminary data on the safety and efficacy of INM-088 treatment. Management expects to file regulatory applications in the first half of the calendar year 2024 to initiate a human clinical trial.
As referenced in a recent international journal publication [Biochimica et Biophysical Acta (BBA) - Molecular Basis of Disease, Volume 1868, Issue 3, 1 March 2022, 166325], InMed’s preclinical research demonstrates that CBN is effective at providing neuroprotection to the retinal ganglion cells and reducing intraocular pressure in glaucoma models, and outperformed several other naturally occurring cannabinoids, including tetrahydrocannabinol (“THC”).
AVCT - OS - 126.64M
https://finance.yahoo.com/quote/AVCT/key-statistics?p=AVCT
$AVCT - KANDY an $AVCT COMPANY WORKING with $ACN $IBM $MSFT $T $GOOG $CGEMY $CAPMF $TMUS $ERIC $INTC $KDDIY $FNCTF $TEF $TU $VOD $ADVT Appears to be getting ready for a BUYOUT, will one of these Companies be the BUYER ? pic.twitter.com/fjm0v6Fb79
— PENNIES to STACKS (@PENNIEStoSTACKS) September 23, 2022
ANPC - OS 39.26M
https://finance.yahoo.com/quote/ANPC/key-statistics?p=ANPC
NEWS
https://finance.yahoo.com/quote/ANPC?p=ANPC
PATENTS
https://patents.justia.com/assignee/anpac-bio-medical-science-co-ltd
Development and evaluation of cancer differentiation analysis technology: a novel biophysics-based cancer screening method
https://www.tandfonline.com/doi/abs/10.1080/14737159.2021.2013201?journalCode=iero20
AnPac Bio Files CDA Device for Breakthrough Medical Device Designation Request with the FDA
https://www.investorwire.com/newsarticle/?qmstory=5468390919453857
NEXI - OS - 22.84M - $1.821
https://finance.yahoo.com/quote/NEXI/key-statistics?p=NEXI
NEWS
https://finance.yahoo.com/quote/NEXI?p=NEXI
TXTM OS - 7,831,465,506 - 05/10/2022
https://www.otcmarkets.com/stock/TXTM/security
WEBSITE
http://www.rsammd.co.za
HISTORICAL
https://ih.advfn.com/stock-market/USOTC/protext-mobility-pk-TXTM/historical/more-historical-data
NEWS
https://www.otcmarkets.com/stock/TXTM/news
FILINGS
https://www.otcmarkets.com/stock/TXTM/disclosure
IPIX OS - 456,580,514 - 06/01/2022
https://www.otcmarkets.com/stock/IPIX/security
WEBSITE
http://www.ipharminc.com
HISTORICAL
https://ih.advfn.com/stock-market/USOTC/innovation-pharmaceuticals-qb-IPIX/historical/more-historical-data
NEWS
https://www.otcmarkets.com/stock/IPIX/news
FILINGS
https://www.otcmarkets.com/stock/IPIX/disclosure
HSCS - HSCSW - OS - 8,112,199
https://ir.heartsciences.com/stock-info
https://heartsciences.com
NEWS
https://finance.yahoo.com/news/heart-test-laboratories-inc-announces-135000283.html
PRESENTATION
https://s3.amazonaws.com/b2icontent.irpass.cc/2729/186737.pdf
HISTORICAL
https://finance.yahoo.com/quote/HSCS/history?p=HSCS
https://finance.yahoo.com/quote/HSCSW/history?p=HSCSW
KTRA - OS - 65.53M - $.22
https://finance.yahoo.com/quote/KTRA/key-statistics?p=KTRA
https://finance.yahoo.com/quote/KTRA?p=KTRA
NXTP - OS - 131.98M - $.3586
https://finance.yahoo.com/quote/NXTP/key-statistics?p=NXTP
https://finance.yahoo.com/quote/NXTP?p=NXTP
